会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • TRACE ELEMENTS
    • 微量元素
    • WO2006027745A2
    • 2006-03-16
    • PCT/IB2005/052917
    • 2005-09-07
    • WARBURTON TECHNOLOGY LIMITEDLAURIE, Robert, NaylorSMITH, William, Alfred
    • LAURIE, Robert, NaylorSMITH, William, Alfred
    • A61K33/34A61K9/0019A61K9/08A61K31/00A61K33/00A61K33/04A61K33/18A61K33/24A61K33/26A61K33/30A61K33/32A61K45/06A61K47/10A61K47/183A61K2300/00
    • The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inpiantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin.
    • 本发明公开了一种微量元素溶液,其包含选自硒,铜,锌,锰和铬的至少一种金属; 和选自维生素,疫苗,生长兴奋剂,驱虫剂,葡聚糖铁,抗生素和同步制剂的组中的至少一种成分。 同步制剂是可注射的激素制剂,不可分解的激素制剂,阴道内激素制剂和其他缓释激素制剂的组合。 抗生素包括口服,可注射和可植入的治疗药物。 疫苗包括抗原和抗原和佐剂的组​​合。 生长兴奋剂包括溶奶油,雌二醇,睾丸激素,孕激素和醋酸维龙胆酮。 驱虫剂包括大分子内酯,leramizoles,苯并咪唑和水杨酰苯胺。 大分子内酯包括多拉菌素,伊维菌素,阿维菌素和莫昔克丁。
    • 6. 发明申请
    • TRACE ELEMENT SOLUTION
    • 追踪元素解决方案
    • WO2017060757A1
    • 2017-04-13
    • PCT/IB2015/057726
    • 2015-10-09
    • WARBURTON TECHNOLOGY LIMITEDSMITH, William Alfred
    • SMITH, William Alfred
    • A23K1/175A61K33/04A61K33/30A61K33/32A61K33/34A61P3/02
    • A61K33/04A61K9/0019A61K9/08A61K33/18A61K33/30A61K33/32A61K33/34A61K2300/00
    • The invention discloses a trace element solution, which comprises at least the following metals: at least 65 mg/ml zinc directly and/or indirectly from mineral EDTA chelate(s) and/or Zn Oxide; at least 10 mg/ml manganese directly and/or indirectly from mineral EDTA chelate(s) and/or Mn carbonate; at least 15 mg/ml copper directly and/or indirectly from mineral EDTA chelate(s) and/or copper sulphate and/or copper oxide and/or carbonate; and at least 5 mg/ml selenium. The trace element solution comprises at least the following: at least 65 mg/ml zinc derived directly and/or indirectly from ZN-EDTA and/or Zn Oxide; at least 10 mg/ml manganese derived directly and/or indirectly from Mn-EDTA and/or Mn carbonate; at least 15 mg/ml copper derived directly and/or indirectly from Cu- EDTA and/or copper oxide and/or copper sulphate and/or copper carbonate; and at least 5 mg/ml selenium derived directly and/or indirectly from Na 2 SeO 4 and/or Na 2 SeO 3 .
    • 本发明公开了一种微量元素溶液,其至少包含以下金属:直接和/或间接从矿物EDTA螯合物和/或氧化锌中至少65mg / ml的锌; 至少10mg / ml锰直接和/或间接来自矿物EDTA螯合物和/或碳酸锰; 至少15mg / ml铜直接和/或间接来自矿物EDTA螯合物和/或硫酸铜和/或氧化铜和/或碳酸盐; 和至少5mg / ml硒。 微量元素溶液至少包含以下物质:至少65mg / ml直接和/或间接从ZN-EDTA和/或氧化锌得到的锌; 从Mn-EDTA和/或碳酸锰直接和/或间接产生的至少10mg / ml的锰; 从Cu-EDTA和/或氧化铜和/或硫酸铜和/或碳酸铜直接和/或间接得到的至少15mg / ml的铜; 和至少5mg / ml从Na 2 SeO 4和/或Na 2 SeO 3直接和/或间接衍生的硒。